[1]CurrentPatentAssignee:MEDICONPHARMACEUTICALS-WO2019/67974,2019,A1Locationinpatent:Paragraph00317;00319
Title: PKA/CREB and NF-κB pathway regulates AKNA transcription: A novel insight into T-2 toxin-induced inflammation and GH deficiency in GH3 cells.
Journal: Toxicology 20171201
Title: Integrated Transcriptional and Proteomic Analysis of Growth Hormone Suppression Mediated by Trichothecene T-2 Toxin in Rat GH3 Cells.
Journal: Toxicological sciences : an official journal of the Society of Toxicology 20151001
Title: Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer.
Journal: Investigational new drugs 20121201
Title: Celecoxib enhances the anti-inflammatory effects of farnesylthiosalicylic acid on T cells independent of prostaglandin E(2) production.
Journal: Inflammation 20121001
Title: Rosiglitazone suppresses lipopolysaccharide-induced matrix metalloproteinase-2 activity in rat aortic endothelial cells via Ras-MEK1/2 signaling.
Journal: International journal of cardiology 20120628
Title: Computer-based identification of a novel LIMK1/2 inhibitor that synergizes with salirasib to destabilize the actin cytoskeleton.
Journal: Oncotarget 20120601
Title: Lipid rafts and functional caveolae regulate HIV-induced amyloid beta accumulation in brain endothelial cells.
Journal: Biochemical and biophysical research communications 20120504
Title: Analgesic potential of intrathecal farnesyl thiosalicylic acid and GW 5074 in vincristine-induced neuropathic pain in rats.
Journal: Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20120501
Title: Farnesylthiosalicylic acid (salirasib) inhibits Rheb in TSC2-null ELT3 cells: a potential treatment for lymphangioleiomyomatosis.
Journal: International journal of cancer 20120315
Title: FTS and 2-DG induce pancreatic cancer cell death and tumor shrinkage in mice.
Journal: Cell death & disease 20120301
Title: Prevention of induced colitis in mice by the ras antagonist farnesylthiosalicylic acid.
Journal: Digestive diseases and sciences 20120201
Title: Ras inhibition by FTS attenuates brain tumor growth in mice by direct antitumor activity and enhanced reactivity of cytotoxic lymphocytes.
Journal: Oncotarget 20120201
Title: Inhibitory effect of farnesylthiosalicylic acid on mediators release by mast cells: preferential inhibition of prostaglandin D(2) and tumor necrosis factor-α release.
Journal: Inflammation 20111001
Title: Inhibition of contact sensitivity by farnesylthiosalicylic acid-amide, a potential Rap1 inhibitor.
Journal: The Journal of investigative dermatology 20111001
Title: Phenotypic reversion of invasive neurofibromin-deficient schwannoma by FTS: Ras inhibition reduces BMP4/Erk/Smad signaling.
Journal: Molecular cancer therapeutics 20110801
Title: A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20110801
Title: ZL11n is a novel nitric oxide-releasing derivative of farnesylthiosalicylic acid that induces apoptosis in human hepatoma HepG2 cells via MAPK/mitochondrial pathways.
Journal: Biochemical and biophysical research communications 20110617
Title: Novel nitric oxide-releasing derivatives of farnesylthiosalicylic acid: synthesis and evaluation of antihepatocellular carcinoma activity.
Journal: Journal of medicinal chemistry 20110512
Title: Chemoprevention of hepatocellular carcinoma. Proof of concept in animal models.
Journal: Acta gastro-enterologica Belgica 20110301
Title: Downregulation of survivin and aurora A by histone deacetylase and RAS inhibitors: a new drug combination for cancer therapy.
Journal: International journal of cancer 20110201
Title: Composite fiber structures with antiproliferative agents exhibit advantageous drug delivery and cell growth inhibition in vitro.
Journal: Journal of pharmaceutical sciences 20110101
Title: The Ras antagonist, farnesylthiosalicylic acid (FTS), decreases fibrosis and improves muscle strength in dy/dy mouse model of muscular dystrophy.
Journal: PloS one 20110101
Title: Ras inhibition induces insulin sensitivity and glucose uptake.
Journal: PloS one 20110101
Title: The combined treatment of Copaxone and Salirasib attenuates experimental autoimmune encephalomyelitis (EAE) in mice.
Journal: Journal of neuroimmunology 20101215
Title: Multiple cellular proteins modulate the dynamics of K-ras association with the plasma membrane.
Journal: Biophysical journal 20101117
Title: Proto-oncogenic H-Ras, K-Ras, and N-Ras are involved in muscle differentiation via phosphatidylinositol 3-kinase.
Journal: Cell research 20100801
Title: Galectin-3 promotes chronic activation of K-Ras and differentiation block in malignant thyroid carcinomas.
Journal: Molecular cancer therapeutics 20100801
Title: Transient receptor potential ankyrin 1 (TRPA1) channel as emerging target for novel analgesics and anti-inflammatory agents.
Journal: Journal of medicinal chemistry 20100722
Title: Dynamic changes in the TRPA1 selectivity filter lead to progressive but reversible pore dilation.
Journal: American journal of physiology. Cell physiology 20100601
Title: Salirasib in the treatment of pancreatic cancer.
Journal: Future oncology (London, England) 20100601
Title: Ras inhibits endoplasmic reticulum stress in human cancer cells with amplified Myc.
Journal: International journal of cancer 20100515
Title: Synthesis and evaluation of nitric oxide-releasing derivatives of farnesylthiosalicylic acid as anti-tumor agents.
Journal: Bioorganic & medicinal chemistry 20100515
Title: Differential requirement of CAAX-mediated posttranslational processing for Rheb localization and signaling.
Journal: Oncogene 20100121
Title: The Ras antagonist farnesylthiosalicylic acid ameliorates experimental myocarditis in the rat.
Journal: Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology 20100101
Title: Phase 1 first-in-human clinical study of S-trans,trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors.
Journal: Cancer chemotherapy and pharmacology 20100101
Title: Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition.
Journal: Molecular cancer 20100101
Title: Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
Journal: Nature chemical biology 20091001
Title: Ras inhibition increases the frequency and function of regulatory T cells and attenuates type-1 diabetes in non-obese diabetic mice.
Journal: European journal of pharmacology 20090815
Title: The Ras inhibitor farnesylthiosalicyclic acid (FTS) prevents nodule formation and development of preneoplastic foci of altered hepatocytes in rats.
Journal: European journal of cancer (Oxford, England : 1990) 20090701
Title: Novel farnesylthiosalicylate (FTS)-eluting composite structures.
Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20090628
Title: Ras inhibition attenuates myocardial ischemia-reperfusion injury.
Journal: Biochemical pharmacology 20090515
Title: New derivatives of farnesylthiosalicylic acid (salirasib) for cancer treatment: farnesylthiosalicylamide inhibits tumor growth in nude mice models.
Journal: Journal of medicinal chemistry 20090108
Title: Salirasib (farnesyl thiosalicylic acid) for brain tumor treatment: a convection-enhanced drug delivery study in rats.
Journal: Molecular cancer therapeutics 20081101
Title: Simvastatin suppresses LPS-induced MMP-1 expression in U937 mononuclear cells by inhibiting protein isoprenylation-mediated ERK activation.
Journal: Journal of leukocyte biology 20081001
Title: Determination of salirasib (S-trans,trans-farnesylthiosalicylic acid) in human plasma using liquid chromatography-tandem mass spectrometry.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20080615
Title: N-Ras or K-Ras inhibition increases the number and enhances the function of Foxp3 regulatory T cells.
Journal: European journal of immunology 20080601
Title: The effect of Ras inhibition on the proliferation, apoptosis and matrix metalloproteases activity in rat hepatic stellate cells.
Journal: Digestive diseases and sciences 20080401
Title: Activation of TRPA1 by farnesyl thiosalicylic acid.
Journal: Molecular pharmacology 20080401
Title: Inhibition of the Ras oncoprotein reduces proliferation of hepatocytes in vitro and in vivo in rats.
Journal: Clinical science (London, England : 1979) 20080101
Title: Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice.
Journal: Cancer chemotherapy and pharmacology 20080101
Title: Inhibitors of chronically active ras: potential for treatment of human malignancies.
Journal: Recent patents on anti-cancer drug discovery 20080101
Title: The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer.
Journal: Methods in enzymology 20080101
Title: Hypoxia enhances metastatic efficiency in HT1080 fibrosarcoma cells by increasing cell survival in lungs, not cell adhesion and invasion.
Journal: Cancer research 20070815
Title: Neuroprotective effects of the Ras inhibitor S-trans-trans-farnesylthiosalicylic acid, measured by diffusion-weighted imaging after traumatic brain injury in rats.
Journal: Journal of neurotrauma 20070801
Title: Suppression of lung cancer tumor growth in a nude mouse model by the Ras inhibitor salirasib (farnesylthiosalicylic acid).
Journal: Molecular cancer therapeutics 20070601
Title: The tumor suppressor neurofibromin confers sensitivity to apoptosis by Ras-dependent and Ras-independent pathways.
Journal: Cell death and differentiation 20070501
Title: Gene expression signature of human cancer cell lines treated with the ras inhibitor salirasib (S-farnesylthiosalicylic acid).
Journal: Cancer research 20070401
Title: Angiotensin II-induced MAPK phosphorylation mediated by Ras and/or phospholipase C-dependent phosphorylations but not by protein kinase C phosphorylation in cultured rat vascular smooth muscle cells.
Journal: Pharmacology 20070101
Title: Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells.
Journal: The Journal of steroid biochemistry and molecular biology 20070101
Title: The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20060915
Title: Suppression of survivin expression in glioblastoma cells by the Ras inhibitor farnesylthiosalicylic acid promotes caspase-dependent apoptosis.
Journal: Molecular cancer therapeutics 20060901
Title: Ras inhibition results in growth arrest and death of androgen-dependent and androgen-independent prostate cancer cells.
Journal: Biochemical pharmacology 20060814
Title: E2F1 identified by promoter and biochemical analysis as a central target of glioblastoma cell-cycle arrest in response to Ras inhibition.
Journal: International journal of cancer 20060801
Title: Farnesylthiosalicylic acid induces caspase activation and apoptosis in glioblastoma cells.
Journal: Cell death and differentiation 20060401
Title: Farnesylthiosalicylic acid: inhibition of proliferation and enhancement of apoptosis of hormone-dependent breast cancer cells.
Journal: Anti-cancer drugs 20060101
Title: Hitting Ras where it counts: Ras antagonism in the basolateral amygdala inhibits long-term fear memory.
Journal: The European journal of neuroscience 20060101
Title: Using inhibitors of prenylation to block localization and transforming activity.
Journal: Methods in enzymology 20060101
Title: Farnesylthiosalicylic acid blocks mammalian target of rapamycin signaling in breast cancer cells.
Journal: International journal of cancer 20051210
Title: Inhibition of Ras attenuates the course of experimental autoimmune neuritis.
Journal: Journal of neuroimmunology 20051101
Title: The inhibition of human mesangial cell proliferation by S-trans, trans-farnesylthiosalicylic acid.
Journal: Kidney international 20050801
Title: Getting at MYC through RAS.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20050615
Title: Disruption of cooperation between Ras and MycN in human neuroblastoma cells promotes growth arrest.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20050615
Title: Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1alpha, causing glycolysis shutdown and cell death.
Journal: Cancer research 20050201
Title: Hydrogen peroxide-induced extracellular signal-regulated kinase activation in cultured feline ileal smooth muscle cells.
Journal: The Journal of pharmacology and experimental therapeutics 20050101
Title: Farnesylthiosalicylic acid inhibits mammalian target of rapamycin (mTOR) activity both in cells and in vitro by promoting dissociation of the mTOR-raptor complex.
Journal: Molecular endocrinology (Baltimore, Md.) 20050101
Title: Characterization of the regulation and functional consequences of p21ras activation in neutrophils by antineutrophil cytoplasm antibodies.
Journal: Journal of the American Society of Nephrology : JASN 20050101
Title: Antiphospholipid antibodies, thrombin and LPS activate brain endothelial cells and Ras-dependent pathways through distinct mechanisms.
Journal: Immunobiology 20050101
Title: The c-Raf inhibitor GW5074 provides neuroprotection in vitro and in an animal model of neurodegeneration through a MEK-ERK and Akt-independent mechanism.
Journal: Journal of neurochemistry 20040801
Title: Treatment of thioacetamide-induced liver cirrhosis by the Ras antagonist, farnesylthiosalicylic acid.
Journal: Journal of hepatology 20040801
Title: The novel Ras antagonist, farnesylthiosalicylate, suppresses growth of prostate cancer in vitro.
Journal: The Prostate 20040301
Title: Restoration of sensitivity to anoikis in Ras-transformed rat intestinal epithelial cells by a Ras inhibitor.
Journal: Cell death and differentiation 20040201
Title: Inhibition of intimal thickening in the rat carotid artery injury model by a nontoxic Ras inhibitor.
Journal: Arteriosclerosis, thrombosis, and vascular biology 20040201
Title: Studies on G-protein alpha.betagamma heterotrimer formation reveal a putative S-prenyl-binding site in the alpha subunit.
Journal: The Biochemical journal 20031201
Title: Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells.
Journal: International journal of cancer 20030610
Title: New approaches to the understanding of tamoxifen action and resistance.
Journal: Endocrine-related cancer 20030601
Title: The Ras inhibitor S-trans, trans-farnesylthiosalicylic acid exerts long-lasting neuroprotection in a mouse closed head injury model.
Journal: Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 20030601
Title: Ras antagonist farnesylthiosalicylic acid (FTS) reduces glomerular cellular proliferation and macrophage number in rat thy-1 nephritis.
Journal: Journal of the American Society of Nephrology : JASN 20030401
Title: Farnesyl thiosalicylic acid chemosensitizes human melanoma in vivo.
Journal: The Journal of investigative dermatology 20030101
Title: Inhibition of ras by farnesylthiosalicylate significantly reduces the levels of autoantibodies in two animal models of the antiphospholipid syndrome.
Journal: Immunobiology 20030101
Title: Functional inhibition of Ras by S-trans,trans-farnesyl thiosalicylic acid attenuates atherosclerosis in apolipoprotein E knockout mice.
Journal: Circulation 20020521
Title: Farnesyl thiosalicylic acid inhibits the growth of melanoma cells through a combination of cytostatic and pro-apoptotic effects.
Journal: International journal of cancer 20020401
Title: The Ras inhibitor S-trans,trans-farnesylthiosalicylic acid chemosensitizes human tumor cells without causing resistance.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20020201
Title: Treatment of MRL/lpr mice, a genetic autoimmune model, with the Ras inhibitor, farnesylthiosalicylate (FTS).
Journal: Clinical and experimental immunology 20011201
Title: The Ras-pathway inhibitor, S-trans-trans-farnesylthiosalicylic acid, suppresses experimental allergic encephalomyelitis.
Journal: Journal of neuroimmunology 20011101
Title: Glutaredoxin protects cerebellar granule neurons from dopamine-induced apoptosis by dual activation of the ras-phosphoinositide 3-kinase and jun n-terminal kinase pathways.
Journal: The Journal of biological chemistry 20010615
Title: Farnesyl-L-cysteine analogs block SAM-induced Parkinson's disease-like symptoms in rats.
Journal: Pharmacology, biochemistry, and behavior 20000801
Title: Dislodgment and accelerated degradation of Ras.
Journal: Biochemistry 19980203
Title: Makovski V, et al. Farnesylthiosalicylic acid (salirasib) inhibits Rheb in TSC2-null ELT3 cells: a potential treatment for lymphangioleiomyomatosis. Int J Cancer. 2012 Mar 15;130(6):1420-9.
Title: Nevo Y, et al. Chapman J. The Ras antagonist, farnesylthiosalicylic acid (FTS), decreases fibrosis and improves muscle strength in dy/dy mouse model of muscular dystrophy. PLoS One. 2011 Mar 22;6(3):e18049.
Title: Charette N, et al. Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition. Mol Cancer. 2010 Sep 22;9:256.
